Gillian L. Hirst

机构：University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center · ORCID：0000-0002-4502-0035

发表论文 285 篇 · 总被引 5662 次 · h-index 29

代表论文

• Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors (2025 · Nature Communications · 被引 16)
• Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial (2025 · Breast Cancer Research · 被引 11)
• Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial. (2025 · Journal of Clinical Oncology · 被引 6)
• Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial (2025 · JCO Precision Oncology · 被引 5)
• Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events (2025 · npj Breast Cancer · 被引 4)
• Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer (2026 · Science Translational Medicine · 被引 3)